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he clinical case of maintaining the patient with 
a sharp transmural myocardial infarction front 
septal areas and tops of the left ventricle, the 
cardiogenic shock of the II degree and alveolar hypostasis 
of lungs are described. In the treatment of the patient 
auxiliary blood circulation in the form of installation of 
an intra aortal balloon counterpulsation in the descending 
department of an aorta was applied. Also, phosphocre-
atine (PCR) of 8 g once with the subsequent appointment 
on 2 g twice a day which has the expressed cardiopro-
tective and antiarrhythmic effect in addition to standard 
therapy in the first days of disease was appointed.
Keywords: phosphocreatine, myocardial infarction, intra 
aortal balloon counterpulsation.
e describe el caso clínico de mantener al pa-
ciente con un infarto transmural agudo en 
las áreas septales frontales y en la parte su-
perior del ventrículo izquierdo, el shock cardiogénico de 
grado II y la hinchazón alveolar de los pulmones. En el 
tratamiento del paciente se aplicó circulación de sangre 
auxiliar en forma de instalación de contrapulsación con 
balón intraaórtico en el departamento descendente de 
una aorta. También se nombró fosfocreatina (PCR) de 8 g 
una vez con la siguiente cita en 2 g dos veces al día, que 
tiene el efecto cardioprotector y antiarrítmico expresado 
además de la terapia estándar en los primeros días de la 
enfermedad.
Palabras clave: Fosfocreatina, infarto de miocardio, con-
trapulsación con balón intraaórtico.
n the practical work of the cardiologist cases when 
despite observance of all modern approaches de-
scribed in clinical recommendations for stabilization 
of a condition of the patient it is necessary to be beyond 
standards1 meet. The use of additional resources can help 
to bring the patient out of critical condition, to thereby 
save his life. One of such medicines is Phosphocreatine 
(PCR)2,3. Preservation of myocardium of acute myocardial 
infarction (AMI) - the major clinical task on which solution 
the next and remote forecast for the patient depends. The 
extensiveness of myocardial infarction (AMI) - the main 
reason for the development of heavy arrhythmias and 
heart failure4. Pilot and clinical trials of biochemical pro-
cesses at ischemia of a myocardium showed a decrease 
of cardiomyocytes (CM) of the level of energy-rich phos-
phates what as Phosphocreatine (PCr) and adenosine 
triphosphate (ATPH)5. This decrease correlates with the 
weight of structural and functional injuries of a myocar-
dium. On this basis, the set of researches of assessment of 
the cardioprotective effect of exogenous Phosphocreatine 
(PCr) is conducted6.
Phosphocreatine (PCr) plays an important role in the me-
tabolism of cells, being an irreplaceable power source and 
adenosine triphosphate (ATPH)7. The set of researches 
confirmed that Phosphocreatine (PCr) exerts a positive im-
pact on the metabolism of the energy of a myocardium, 
improving excitability, conductivity, and contractility of 
cardiomyocytes (CM), thereby minimizing the risk of de-
veloping of arrhythmia and keeping the contractile ability 
of a myocardium8.
Fibrosis of myocardium is the leading pathological change 
at an acute myocardial infarction (AMI) and is character-
ized by the excessive adjournment of extracellular matrix 
(ECM)9. Fibrosis of a cardiac muscle leads to the devel-
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(LV), different developing of arrhythmias, followed by pro-
gressing heart failure (HF)5,7. Fibroblast of a myocardium, 
being the most widespread cell type, play a crucial role in 
the course of fibrosis. Interaction of factors of inflamma-
tion and cytokine contributes to the continuous develop-
ment of fibrosis of a myocardium. The modern cardiology 
is concentrated on delay, prevention, regression of fibrosis 
of heart, but effective methods of treatment and today 
practically does not exist10,11.
For patients with acute myocardial infarction (AMI) the 
cause of death of cardiomyocytes (CM) is their apoptosis. 
A large number of research works proved that apoptosis 
of cardiomyocytes (CM) is the key moment in progressing 
heart failure (HF) at various diseases of the heart1,12,13.  
The positive effect of Phosphocreatine (PCr) at the devel-
opment of fibrosis of a cardiac muscle was exposed to 
scientific consideration in experiments on animals10,11. 
So, the Chinese scientific Dai H, Chen L, etc. researched 
rats for studying of influence of Phosphocreatine (PCr) on 
myocardium fibrosis. For induction of fibrosis of a myocar-
dium at animals used Isoproterenol (ISO)14. Reference 14: 
Osipova, O. A., et al. Not Dai H, Chen L, Phosphocreatine 
(PCr) entered at the following stage of an experiment sup-
pressed apoptosis of cardiomyocytes (CM) that led to the 
reduction of the severity of fibrosis due to the reduction of 
accumulation of collagen and the related markers. Their 
activity was high after Isoproterenol activation (ISO) and 
the cancellation of the introduction of Phosphocreatine 
(PCr) that proved a possibility of its use as the means of 
preventing myocardium fibrosis. 
According to the meta-analysis of 23 controlled types of 
research with the participation of 3400 patients Phospho-
creatine (PCr) authentically reduces the general lethal-
ity, prevents the development of complications of acute 
myocardial infarction (AMI) and chronic heart failure of 
chronic heart failure (CHF)3. 
Main Part: Our clinical case can serve as an example of a 
positive effect on the use of phosphocreatine (PCr).
Patient N., 76 years, came to Head of Intensive cardiac 
care unit, “Heart Clinic” Ltd on April 26, 2018. It is de-
livered by a crew of emergency medical service in critical 
condition with complaints to the pains expressed press-
ing, squeezing behind a breast irradiating in the left 
hand which is followed by the sharp general weakness 
expressed by short wind, cold sticky then. From the an-
amnesis it is found out: the above-stated complaints arose 
suddenly about 6 h 30 min. 26.04.2018 at rest. The crew 
of emergency medical service on the electrocardiogram 
(ECG) recorded ST-segment elevation to 3 mm in assign-
ments of V2-V5. With suspicion of acute myocardial in-
farction (AMI) the patient is brought to LLC Clinic of Heart 
“Heart Clinic” Ltd for carrying out of coronary angiogra-
phy (CAG) and the solution of a question of further tac-
tics of treatment. According to the patient, about 5 years 
have hypertension with the maximum figures of arterial 
pressure (AP) of 170/90 mm Hg. did not take hypotensive 
drugs regularly. Within the last six months noted episodes 
of the short-term pressing pains behind a breast three 
times. We were stopped independently at rest. In medical 
institutions did not ask for medical care.
At objective survey: consciousness of the patient is con-
fused, is periodically disoriented in the place and time. 
Normosthenic constitution, moderate food. Integuments 
and visible mucous pale. The mottled acrocyanosis, the 
increased humidity of integuments is observed.  Auxil-
iary muscles, the percutaneous - overall surface of lungs 
a pulmonary sound participate in the act of breathing. 
Breathing rate (BR) 26 in a minute, SpO2 84%. Auscul-
tatory rigid breath weakened in the lower departments 
of lungs, damp mixed rattles in the lower and average 
departments on both sides in a large number. Veins necks 
bulk up. Tones of heart rhythmical, are muffled, the noise 
has not listened. Easing of the I tone is observed. Heart 
rate (HR) of 98 beats per minute. Arterial pressure (AP) 
= 85/55 mm Hg. Language is damp, it is not laid over. 
The stomach of the correct form, symmetric, evenly par-
ticipates in the act of breath, at a palpation soft, pain-
less. The liver, a spleen is not palpated. Active vermicu-
lar movement. The lumbar area is visually not changed, 
a beating symptom negative on both sides. Peripheral 
hypostases are absent. At revenues to an electrocardio-
gram (ECG) (fig. 1) against the background of a sinus 
rhythm, the complete blockade of the right bundle of 
His, ST-segment elevation to 9 mm in assignments of 
V2-V5 is recorded. In the general blood test, it is noted 
leucocytosis 13,13х109/l. In biochemical blood test - in-
crease in cardio specific enzymes: troponin I - 5,53ng/ml. 
Fig. 1. ECG on admission
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The clinical picture was regarded as a sharp transmural 
myocardial infarction front septal areas and tops of LV, 
complicated by the cardiogenic shock of the II degree 
and alveolar hypostasis of lungs. At a stage of ambulance 
medical care - statement of an intravenous catheter in a 
cubital vein of the top left extremity is provided, oxygen 
therapy, intravenous administration of heparin of 4000 
Pieces, are orally given load doses of antiaggregant (ace-
tylsalicylic acid of 300 mg, clopidogrel 600 mg). In a hos-
pital correction of acute left ventricular failure (ALVF) - in-
travenous support with inotropic medicines (a dopamine, 
dobutamine) under control of indicators of hemodynam-
ics, intravenous bolus administration of furosemide with 
the subsequent infusion through a perfusion under con-
trol of a diuresis, intravenous administration of morphine 
with the anesthetizing purpose is immediately begun and 
for unloading of a small circle of blood circulation, the uric 
catheter is established.
According to the emergency indications, the patient is 
brought in an X-ray operating room for carrying out CAG 
with possible implantation of the stent in a symptom - the 
connected artery for the restoration of blood supply of 
a myocardium. On coronary angiography (CAG) (fig. 2) 
occlusion of a proximal third of left anterior descending 
artery (LAD), decides on lack of contrasting of the disteel 
course, a stenosis of 40% in an average third of the left 
circumflex coronary artery (LCX), the left type of coronary 
blood supply.
The decision to execute a recanalization of occlusion of 
the left ventricle (LAD) with the subsequent stenting is 
made. It is implanted a stent to Multi-Link (D - 4mm, L-
28mm). On a control angiography (CAG) (fig. 3, 4) filling 
of disteel departments of the left anterior descending ar-
tery (LAD) - TIMI 2.
Considering unstable hemodynamics, not stopped swelled 
lungs, in the descending department of an aorta of intra-
aortic balloon counter-pulsator (IABCS) is established. The 
patient is transferred to the chamber of intensive therapy. 
Against the background of the carried-out therapy within 
the first days’ complaints to the moderate pressing pains 
behind a breast, the expressed short wind, unproductive 
cough, clinic of acute left ventricular failure (ALVF), insta-
bility of hemodynamics remained.  
In the first days of hospitalization, there was a failure 
of a warm rhythm in atrial fibrillation (AF) to heart rate 
(HR) from 100 to 134 bt. a minute. To ensure adequate 
infusion of medicines and control of the central venous 
pressure, the catheterization of the right jugular vein is 
made. Correction of acute left ventricular failure (ALVF) 
by intravenous administration of inotropic medicines (a 
dopamine, dobutamine) under control of indicators of 
hemodynamics, the intravenous dosed administration of 
loopback diuretics (furosemide) under control of indica-
tors of a diuresis, adequate anesthesia by narcotic analge-
sics is continued (fentanyl, morphine, promedol), for the 
purpose of prevention of a further clottage intravenous 
infusion of heparin under control of ALVF and clot time 
is begun, for restoration of a sinus rhythm and preven-
tion of life-threatening violations of a rhythm (fibrillation 
of ventricles) intravenous infusion of an amiodaron under 
control of indicators of hemodynamics and control of the 
electrocardiogram (ECG) on the cardio monitor is begun. 
At an echocardiography fraction of emission of left ven-
tricular ejection fraction (LVEF) = 31%
Considering not stopped left ventricular failure (LVF), the 
remaining picture of cardiogenic shock with the cardio-
protective purpose could be added to therapy Phospho-
creatine (PCr) 8 g once with the subsequent appointment 
on 2 g twice a day.
27.04.2018 some positive dynamics are noted - angino-
sis pains were stopped, a short wind at rest considerably 
decreased, the sinus rhythm was restored. Tones of heart 
rhythmical, are muffled. Arterial pressure (AP) 108/62mm 
hg, of heart rate (HR) 91 bt. in a minute. Considerable 
reduction of damp small-bubble rattles in the lower de-
partments of lungs was noted. Breathing rate (BR) 20 a 
minute. SpO2 90-95%. Work of IABCS, hemodynamics 
support as an infusion of vasoconstrictor was continued. 
At a control echocardiography increase in the global con-
tractive ability of a myocardium up to 35% is noted. The 
course of treatment Phosphocreatine (PCr) on 2 g twice a 
day is continued.
29.04.2018 - permanent stabilization of hemodynam-
ics, on electrocardiograms (ECG) a steady sinus rhythm. 
IABCS is removed. Tones of heart rhythmical, are muffled, 
AP within a day within 100-114/60-68 mm Hg, HR within 
100 bt. in a minute. In lungs single damp small-bubble 
rattles in the lower departments of lungs on both sides. 
Breathing rate (BR) within 20-22 in a minute, SpO2 92 
without oxygen insufflation. The speed of the infusion of 
vasoconstrictor is reduced. At control, biochemical blood 
test reduction of indicators of cardio specific markers is 
noted. At echocardiography - an increase in the global 
contractive ability of a myocardium - FV of 39%. The 
course of treatment Phosphocreatine (PCr) on 2 g twice 
a day is continued.
1.05.2018 infusion of vasoconstrictor is gradually stopped. 
The patient gradually becomes more active. Anginozic 
pains do not recur, notes the feeling of shortage of air at 
the minimum physical activity. Tones of heart rhythmical, 
are muffled. AD within a day = 97-100/60-70 mm Hg., 
TSS = 94-98 bt. in a minute. In lungs single crepitant in 
the lower departments of lungs on both sides, ChDD - 18 
in a minute, SpO2 92-98%. On control EHO-KG - with-
out negative dynamics, an increase in the global contrac-
tive ability of a myocardium - LVEF of 41% is noted. The 
course of treatment Phosphocreatine (PCr) on 2 g twice a 
day is continued.
Against the background of the carried-out therapy the 
condition of the patient was stabilized, is made active 
on the ward mode. During the period from 3.05.2018 to 
273
Revista Latinoamericana de Hipertensión. Vol. 14 - Nº 4, 2019www.revhipertension.com
7.05.2018 a state with positive dynamics. The patient is 
made active on the IIB mode. Anginal pains did not re-
cur, notes the feeling of shortage of air at the minimum 
physical activity. In lungs developments of stagnation in 
the form of crepitant rattles in the lower departments of 
lungs remain. Hemodynamics is stable. At control blood 
test normalization of the level of leukocytes of blood is 
observed (8,1х109/l). In biochemical blood test normal-
ization of cardio specific markers. On the electrocardio-
gram (ECG) (fig. 5) - a rhythm sinus, violations of a warm 
rhythm did not repeat from the date of the purpose of 
Phosphocreatine (PCr). LVEF = 45%.
Fig. 2. Initial coronary angiography
Fig. 3, 4. Control of coronary angiography.
Fig. 5. ECG at discharge
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n the presented clinical case of maintaining the pa-
tient with a sharp transmural myocardial infarction 
front septal areas and tops of the left ventricle, car-
diogenic shock of the II degree and alveolar hypostasis of 
lungs, Phosphocreatine (PCr) has the expressed cardiopro-
tective and antiarrhythmic effect at addition to standard 
therapy of an acute myocardial infarction  (AMI) in the 
first days of a disease, including against the background 
of carrying out auxiliary blood circulation.
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